A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

NCT06519682 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

High Grade Glioma
Replication Repair Deficient

Interventions

DRUG: Nivolumab
RADIATION: Radiation

Sponsor

Daniel Morgenstern

Collaborators

[object Object]
[object Object]